

## Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

**STOCKHOLM, Sweden, 24 September 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the first patient has been enrolled in the Phase III clinical study with AKP02G2.**

The drug candidate AKP02G2 combines calcipotriol and betamethasone and is based on Lipidor's patented AKVANO® technology. The goal of AKP02G2 is to offer a patient-friendly and fast-drying spray for the treatment of mild to moderate psoriasis with equivalent effect to the market-leading Enstilar.

The clinical Phase III study is being conducted by Cliantha, the company's contracted CRO (Clinical Research Organisation), which together with Lipidor has carried out solid preparatory work to enable the start of the study according to plan. As of today, the work has resulted in the first of the 294 patients being included in the study.

"It is extremely positive and an important milestone for us to have now recruited the first patient and that the clinics are ready to receive patients. We look forward to presenting the first results from the study in about six months", says Ola Holmlund, CEO of Lipidor.

Lipidor will follow the recruitment closely and keep the market updated.

### Publication

The information was provided for publication by Lipidor's CEO on 24 September 2024 at 6.30 pm (CEST).

### For more information, please contact:

Ola Holmlund, CEO, Lipidor AB (publ)

Telephone: +46 (0) 72 50 70 369

Email: [ola.holmlund@lipidor.se](mailto:ola.holmlund@lipidor.se)

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

## About Lipidor AB

Lipidor AB ([www.lipidor.se](http://www.lipidor.se)) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor's priority project is AKPO2G2, which focusses on psoriasis.

## About AKVANO®

AKVANO® is an innovative water-free and sprayable technology for formulating medicines and is particularly suitable for local application on, for example, the skin. AKVANO® is made up of carefully selected lipids which, together with a volatile solvent, form the carrier of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of active components in the formulation. When applied to the skin, the solvent evaporates and a thin lipid layer is formed on the skin surface for effective release of the active substance.

## Attachments

[Lipidor announces first patient enrolled in Phase III study of AKPO2G2 for topical treatment of psoriasis](#)